Hemay007 / Tianjin Hemay Pharma - LARVOL DELTA

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis (clinicaltrials.gov) - P2 | N=70 | Terminated | Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd | Recruiting ➔ Terminated; Due to the difficulty to recruit enough patients, the study was terminated.

Trial termination • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=140 | Completed | Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Jun 2023 | Trial primary completion date: Dec 2023 ➔ Jun 2023

Trial completion • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=140 | Active, not recruiting | Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=70; Recruiting; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=70; Active, not recruiting; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd; Recruiting ➔ Active, not recruiting; N=288 ➔ 70

Clinical • Enrollment change • Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=288; Recruiting; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=288; Recruiting; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=288; Not yet recruiting; Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd

Clinical • New P2 trial